PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-12.98%
Negative revenue growth while ACB.TO stands at 23.77%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-5.67%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-77.54%
Negative EBIT growth while ACB.TO is at 178.75%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-77.54%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-23.37%
Negative net income growth while ACB.TO stands at 137.46%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-11.75%
Negative EPS growth while ACB.TO is at 150.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-11.75%
Negative diluted EPS growth while ACB.TO is at 150.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
10.30%
Share count expansion well above ACB.TO's 0.19%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
10.30%
Diluted share count expanding well above ACB.TO's 0.01%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-213.44%
Negative OCF growth while ACB.TO is at 139.64%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-293.67%
Negative FCF growth while ACB.TO is at 112.02%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
-49.02%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-38.88%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-73.69%
Negative 10Y OCF/share CAGR while ACB.TO stands at 168.23%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
63.22%
Below 50% of ACB.TO's 131.70%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
80.56%
Positive 3Y OCF/share CAGR while ACB.TO is negative. John Neff might see a big short-term edge in operational efficiency.
-1805.63%
Negative 10Y net income/share CAGR while ACB.TO is at 115.68%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-176.55%
Negative 5Y net income/share CAGR while ACB.TO is 688.86%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
51.73%
3Y net income/share CAGR 50-75% of ACB.TO's 101.96%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
9259.09%
10Y equity/share CAGR above 1.5x ACB.TO's 137.37%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-35.28%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-58.67%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.30%
Our AR growth while ACB.TO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
4.84%
Inventory growth well above ACB.TO's 8.36%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-1.69%
Negative asset growth while ACB.TO invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-8.28%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
0.29%
We have some new debt while ACB.TO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-73.35%
Our R&D shrinks while ACB.TO invests at 32.84%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-19.29%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.